InspireMD (Nasdaq: NSPR) announced FDA approval for its flagship CGuard Prime Carotid Stent System, a next-generation mesh-covered stent developed to prevent stroke by treating carotid artery disease. The approval marks a major milestone for the company and also triggers the second of four milestone-driven warrant tranches tied to its $113.6 million private placement announced in May 2023.

If fully exercised, the warrants are expected to provide $17.9 million in gross proceeds. The company plans to use the funding to support the imminent U.S. commercial launch of CGuard Prime, pursue new regulatory opportunities, and advance next-generation stent platforms based on its proprietary MicroNet mesh technology.

The FDA approval is based on positive results from InspireMD’s pivotal C-GUARDIANS trial, which enrolled 316 patients across 24 sites in the United States and Europe. The study evaluated CGuard Prime for use in both symptomatic and asymptomatic patients undergoing carotid artery stenting (CAS).

CGuard Prime delivered the lowest 30-day and 1-year major adverse event (MAE) rates ever reported in a pivotal carotid intervention study, with a 0.95 percent event rate at 30 days and a 1.93 percent event rate at one year.

“The C-GUARDIANS clinical trial provides strong scientific evidence to support the neuro-protective benefits of the next generation MicroNet mesh technology,” said Dr. D. Chris Metzger, System Vascular Chief at OhioHealth and U.S. Principal Investigator. “These excellent results were in patients who were at high risk for carotid endarterectomy.”

“I am proud to announce the PMA approval of CGuard Prime,” said Marvin Slosman, Chief Executive Officer of InspireMD. “This is a pivotal milestone for the Company after many years of commitment. Our approval marks a true breakthrough in the treatment of carotid disease.”

Slosman added that CGuard Prime’s design is centered around a mesh-based barrier that helps prevent post-procedure embolic events. The company reports that over 65,000 CGuard stents have already been implanted worldwide, and more than 2,000 patients have participated in related studies.

The FDA’s premarket approval (PMA) is expected to catalyze InspireMD’s U.S. expansion. The company is preparing for an immediate commercial launch and plans to leverage the strong clinical dataset to pursue broader clinical adoption.

Product Profile

The CGuard Prime system combines an open-cell nitinol stent frame with the smallest mesh pore size among available carotid stents. This dual-structure design is intended to reduce the risk of plaque protrusion through the stent and to sustain long-term embolic protection.

Investor Outlook

The $17.9 million potential capital from the triggered warrant tranche offers InspireMD runway for near-term commercial execution and product development. Additional warrant tranches tied to clinical and commercial milestones remain outstanding, offering future funding flexibility.

With the FDA approval in place and a data-backed product in hand, InspireMD is positioned to enter the U.S. market with momentum. Investor focus will now shift toward execution of the U.S. launch and updates on broader pipeline initiatives powered by the company’s MicroNet mesh technology.